S&P 500   3,677.77 (+0.24%)
DOW   30,056.47 (+0.58%)
QQQ   304.70 (+0.28%)
AAPL   122.87 (-0.17%)
MSFT   214.66 (-0.33%)
FB   283.88 (-1.27%)
GOOGL   1,828.18 (+0.18%)
AMZN   3,202.58 (-0.03%)
TSLA   586.61 (+3.13%)
NVDA   535.52 (-1.16%)
BABA   266.14 (+1.84%)
CGC   28.66 (+1.70%)
GE   10.60 (+1.63%)
MU   70.59 (+2.14%)
AMD   92.25 (-1.59%)
T   29.06 (-0.10%)
NIO   46.36 (-3.38%)
F   9.26 (+0.65%)
ACB   10.86 (-0.82%)
NFLX   500.80 (-0.51%)
BA   238.90 (+6.72%)
GILD   60.98 (-0.25%)
DIS   153.40 (-0.14%)
S&P 500   3,677.77 (+0.24%)
DOW   30,056.47 (+0.58%)
QQQ   304.70 (+0.28%)
AAPL   122.87 (-0.17%)
MSFT   214.66 (-0.33%)
FB   283.88 (-1.27%)
GOOGL   1,828.18 (+0.18%)
AMZN   3,202.58 (-0.03%)
TSLA   586.61 (+3.13%)
NVDA   535.52 (-1.16%)
BABA   266.14 (+1.84%)
CGC   28.66 (+1.70%)
GE   10.60 (+1.63%)
MU   70.59 (+2.14%)
AMD   92.25 (-1.59%)
T   29.06 (-0.10%)
NIO   46.36 (-3.38%)
F   9.26 (+0.65%)
ACB   10.86 (-0.82%)
NFLX   500.80 (-0.51%)
BA   238.90 (+6.72%)
GILD   60.98 (-0.25%)
DIS   153.40 (-0.14%)
S&P 500   3,677.77 (+0.24%)
DOW   30,056.47 (+0.58%)
QQQ   304.70 (+0.28%)
AAPL   122.87 (-0.17%)
MSFT   214.66 (-0.33%)
FB   283.88 (-1.27%)
GOOGL   1,828.18 (+0.18%)
AMZN   3,202.58 (-0.03%)
TSLA   586.61 (+3.13%)
NVDA   535.52 (-1.16%)
BABA   266.14 (+1.84%)
CGC   28.66 (+1.70%)
GE   10.60 (+1.63%)
MU   70.59 (+2.14%)
AMD   92.25 (-1.59%)
T   29.06 (-0.10%)
NIO   46.36 (-3.38%)
F   9.26 (+0.65%)
ACB   10.86 (-0.82%)
NFLX   500.80 (-0.51%)
BA   238.90 (+6.72%)
GILD   60.98 (-0.25%)
DIS   153.40 (-0.14%)
S&P 500   3,677.77 (+0.24%)
DOW   30,056.47 (+0.58%)
QQQ   304.70 (+0.28%)
AAPL   122.87 (-0.17%)
MSFT   214.66 (-0.33%)
FB   283.88 (-1.27%)
GOOGL   1,828.18 (+0.18%)
AMZN   3,202.58 (-0.03%)
TSLA   586.61 (+3.13%)
NVDA   535.52 (-1.16%)
BABA   266.14 (+1.84%)
CGC   28.66 (+1.70%)
GE   10.60 (+1.63%)
MU   70.59 (+2.14%)
AMD   92.25 (-1.59%)
T   29.06 (-0.10%)
NIO   46.36 (-3.38%)
F   9.26 (+0.65%)
ACB   10.86 (-0.82%)
NFLX   500.80 (-0.51%)
BA   238.90 (+6.72%)
GILD   60.98 (-0.25%)
DIS   153.40 (-0.14%)
Log in
NASDAQ:CDXS

Codexis Stock Forecast, Price & News

$17.12
-1.76 (-9.32 %)
(As of 12/3/2020 11:27 AM ET)
Add
Compare
Today's Range
$16.90
Now: $17.12
$18.45
50-Day Range
$12.97
MA: $15.33
$19.05
52-Week Range
$8.43
Now: $17.12
$19.30
Volume75,744 shs
Average Volume305,971 shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.12
Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Codexis logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.11 out of 5 stars


Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100
Employees161

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$68.46 million
Book Value$1.53 per share

Profitability

Net Income$-11,940,000.00

Miscellaneous

Market Cap$1.01 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$17.12
-1.76 (-9.32 %)
(As of 12/3/2020 11:27 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Codexis (NASDAQ:CDXS) Frequently Asked Questions

How has Codexis' stock price been impacted by Coronavirus (COVID-19)?

Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDXS stock has increased by 72.6% and is now trading at $17.47.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Codexis?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Codexis
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Codexis?

Wall Street analysts have given Codexis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Codexis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Codexis' next earnings date?

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Codexis
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.06. The biotechnology company had revenue of $18.39 million for the quarter, compared to the consensus estimate of $14.97 million. Codexis had a negative net margin of 31.08% and a negative return on equity of 21.25%.
View Codexis' earnings history
.

What price target have analysts set for CDXS?

3 brokers have issued 1-year price targets for Codexis' stock. Their forecasts range from $16.00 to $21.00. On average, they expect Codexis' share price to reach $18.50 in the next year. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for Codexis
.

Are investors shorting Codexis?

Codexis saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,770,000 shares, an increase of 10.7% from the October 31st total of 4,310,000 shares. Based on an average daily trading volume, of 303,100 shares, the days-to-cover ratio is presently 15.7 days. Currently, 8.5% of the company's stock are short sold.
View Codexis' Short Interest
.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Canopy Growth (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Who are Codexis' key executives?

Codexis' management team includes the following people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 56, Pay $1.06M)
  • Mr. Ross Taylor Jr., M.B.A., Sr. VP & CFO (Age 57, Pay $471.53k)
  • Dr. Karl A. Schoene Ph.D., Sr. VP of Devel. & Operations
  • Dr. Gjalt Huisman Ph.D., Sr. VP of Strategic Devel. & GM of Biotherapeutics
  • Mr. Rob Wilson Ph.D., Sr. VP & GM of Performance Enzymes
  • Dr. Stefan Lutz Ph.D., Sr. VP of Research
  • Mr. Robert Sato M.B.A., Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 74)
  • Dr. Davinder Singh Brar, Special Advisor to the Board (Age 68)

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.73%), Wells Fargo & Company MN (4.07%), William Blair Investment Management LLC (3.73%), Vivo Capital LLC (2.49%), ARK Investment Management LLC (2.39%) and State Street Corp (2.04%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis
.

Which institutional investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, William Blair Investment Management LLC, Nikko Asset Management Americas Inc., Essex Investment Management Co. LLC, Natixis, Wells Fargo & Company MN, State Street Corp, and Aigen Investment Management LP. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, and Thomas R Baruch.
View insider buying and selling activity for Codexis
.

Which institutional investors are buying Codexis stock?

CDXS stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Trigran Investments Inc., BlackRock Inc., Roubaix Capital LLC, Skandinaviska Enskilda Banken AB publ, SG Americas Securities LLC, Morgan Stanley, and Arrowstreet Capital Limited Partnership. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis
.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $17.47.

How big of a company is Codexis?

Codexis has a market capitalization of $1.04 billion and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 161 workers across the globe.

What is Codexis' official website?

The official website for Codexis is www.codexis.com.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.